Ximelagatran pharmacodynamics

Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran a mini-review. Thromb Res 2003 109(suppl I ) S9-S I 5. 

Eriksson UG, Bredberg U, Gislen K, et al, Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003 59 35-43. 

I Eriksson UG, Johansson S, Attman PO, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacoki net 2003 42 743-753. 

Wahlander K, Eriksson-Lepkowska M, Frison L, etal. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003 42 755-764. 

Sarich TC, Schutzer KM, Dorani H, et al. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 2004 44 928-934. 

Wolzt M, Sarich TS, Eriksson UG. Pharmacokinetics and pharmacodynamics of ximelagatran. Semin Vase Med 2005 5 245-253. 

Sarich TC, Teng R, Peters GR, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003 42 485 -92,... 

In a single-dose study in 24 healthy subjects, simultaneous administration of ximelagatran 24 mg and enteric-coated diclofenac 50 mg caused no change in the pharmacokinetics of either drug. In this study, there was also no additional effect of the combination on activated partial thromboplastin time or capillary bleeding time, suggesting that no pharmacodynamic interaction occurs. ... 

The findings of a pharmacokinetic interaction with a small pharmacodynamic effect indicate that further study is needed. Until more is known, it would certainly be prudent to be cautious if ximelagatran is used in patients taking erythromycin, although note that the pharmacoc namic effect was small and all patients tolerated the combination well. ... 

Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG. Pharmacdcinetics and pharmacodynamics of melagatran, the active form ofthe oral direct thrombin inhibitcx ximelagatran, are not influenced by acetylsalicy lie acid. EurJ Clin Pharmacol (2003) 59,283-9. 

---